Core Insights - The AI Fund Caizheng Asset Management Healthcare Mixed A (018484) reported a profit of 24.79 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1341 yuan [2] - The fund's net value growth rate for the reporting period was 12.31%, and the fund size reached 131 million yuan by the end of Q2 [2][14] - The fund focuses on long-term investments in pharmaceutical and healthcare stocks, with a unit net value of 1.2 yuan as of July 18 [2] Performance Metrics - As of July 18, the fund's one-year cumulative net value growth rate was 40.05%, ranking 68 out of 133 comparable funds [3] - The fund's three-month and six-month cumulative net value growth rates were 27.15% and 38.72%, ranking 71 out of 138 and 73 out of 138 respectively [3] - The fund has maintained an average stock position of 85.93% since inception, with a peak of 92.29% at the end of Q1 2024 [13] Risk and Return Analysis - The fund's Sharpe ratio since inception is 0.2868, indicating a moderate risk-adjusted return [7] - The maximum drawdown since inception is 29.68%, with the largest quarterly drawdown occurring in Q1 2024 at 21.64% [10] Investment Strategy - The fund manager, Yi Xiaojin, emphasizes identifying investment targets that can benefit from the aging economy and domestic demand evolution, focusing on sectors such as innovative drugs, medical devices, and pharmacies [2] - The fund aims to invest in companies that are actively embracing international expansion, particularly in medical consumables, raw materials, and innovative medical devices [2] - The fund holds a concentrated portfolio, with the top ten holdings including companies like Rejing Biology, Zhaoyan New Drug, and WuXi AppTec [17]
财通资管医疗保健混合A：2025年第二季度利润2479.39万元 净值增长率12.31%
Sou Hu Cai Jing·2025-07-21 10:00